Loretta Ngu

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival

M. Rafferty, P. McKay, D. Culligan, 2020, British journal of haematology.

Autoimmune haemolytic anaemia associated with epstein barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report

R. D'Souza, Alexander J. Hamilton, Lynsey H Webb, 2015, BMC Nephrology.

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

K. Ramasamy, S. Basu, R. Soutar, 2022, Hematology.

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

N. Potter, C. Craddock, N. Russell, 2022, Blood.

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients

K. Ramasamy, S. Basu, R. Soutar, 2023, British journal of haematology.

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

N. Potter, C. Craddock, N. Russell, 2023, Leukemia.

Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML

M. Jädersten, S. Knapper, I. Tiong, 2023, Blood advances.